Propanc Biopharma (PPCB) Share-based Compensation (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Share-based Compensation of $3.0 million for Q3 2025, up 106.47% quarter-over-quarter from -$46.7 million in Q2 2025.
Propanc Biopharma (PPCB) Share-based Compensation (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Share-based Compensation for 13 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Share-based Compensation changed N/A year-over-year to $3.0 million; the TTM figure through Sep 2025 stood at -$43.7 million (changed N/A YoY), while the FY2025 annual figure was $4.6 million, changed N/A from the prior year.
- Share-based Compensation climbed to $3.0 million in Q3 2025 per PPCB's latest filing, from -$46.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.0 million in Q3 2025 and bottomed at -$46.7 million in Q2 2025.
- Historically, Share-based Compensation has averaged -$4.8 million across 3 years, with a median of $20718.0 in 2021.
- Annual changes were most pronounced in 2021 — Share-based Compensation surged 543.99% — and 2022, when it sank 336.43%.
- Propanc Biopharma's Share-based Compensation stood at $20718.0 in 2021, then slumped by 88.38% to $2408.0 in 2022, then soared by 125506.52% to $3.0 million in 2025.
- Business Quant data shows PPCB's Share-based Compensation at $3.0 million in Q3 2025, -$46.7 million in Q2 2025, and $2408.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.02 Mn |
| Sep 30, 2025 | 3.02 Mn |
| Jun 30, 2025 | -46.73 Mn |
| Jun 30, 2025 | -46.73 Mn |
| Dec 31, 2022 | 2,408.00 |
| Dec 31, 2022 | 2,408.00 |
| Jun 30, 2022 | -149,939.00 |
| Jun 30, 2022 | -149,939.00 |
| Mar 31, 2022 | 20,718.00 |
| Mar 31, 2022 | 20,718.00 |
| Dec 31, 2021 | 20,718.00 |
| Dec 31, 2021 | 20,718.00 |
| Sep 30, 2021 | 133,422.00 |
| Sep 30, 2021 | 133,422.00 |
| Jun 30, 2021 | 63,418.00 |
| Jun 30, 2021 | 63,418.00 |
| Mar 31, 2021 | 20,718.00 |
| Mar 31, 2021 | 20,718.00 |
| Dec 31, 2020 | 20,718.00 |
| Dec 31, 2020 | 20,718.00 |